Weight-loss drugs like semaglutide and tirzepatide do cause muscle loss alongside fat loss, but the problem is largely preventable with the right interventions that most patients never hear about. Between 25% and 45% of the weight people lose on GLP-1 medications comes from lean muscle mass rather than fat, according to data from major clinical trials. Yet the conversation at the pharmacy counter focuses almost entirely on nausea and insurance coverage, leaving patients confused when they notice their arms getting smaller or feel weaker months into treatment.

The muscle loss itself is not unique to GLP-1 drugs. Any significant calorie deficit, whether from traditional dieting, bariatric surgery, or appetite-suppressing medications, triggers some lean mass loss. What matters clinically is the ratio of fat lost to muscle lost, the total amount of muscle shed, and whether that loss affects a person's strength and function. On those measures, GLP-1s are not inherently worse than other weight-loss approaches. The real concern is specific groups of people who face much higher risk.

Who Is Most Vulnerable to Muscle Loss on GLP-1 Drugs?

Three populations deserve urgent attention from healthcare providers: older adults, people with low baseline muscle mass, and those losing weight very rapidly. Adults over 65 are already losing muscle naturally as part of aging. When GLP-1 therapy causes an additional 10 pounds of lean mass loss, it is not a minor side effect. It becomes a functional capacity issue with real consequences for fall risk, independence, and quality of life.

Sedentary people who are obese often carry less muscle than their weight suggests. Losing a substantial proportion of what little muscle they have matters more than it would for someone who is well-muscled. Finally, the faster the weight loss occurs, the higher the proportion of lean mass in the total weight lost. Patients eating very little, sometimes below 1,000 calories per day because GLP-1s suppress appetite so effectively, face higher muscle loss risk than those maintaining adequate protein intake.

How to Preserve Muscle While Taking GLP-1 Medications

• Protein Target: Aim for 1.2 to 1.6 grams of protein per kilogram of body weight daily, which is higher than most people currently eat. For a 200-pound person, that translates to 109 to 145 grams of protein daily. On a suppressed appetite, hitting this target requires intentionality, with every meal needing a protein anchor even when hunger is absent.
• Resistance Training: Perform resistance training two to three times per week targeting major muscle groups. Patients do not need to become athletes; they simply need enough resistance work to signal to their body that muscle is still needed. A prospective study of 200 adults on semaglutide or tirzepatide combined with protein-rich meals and resistance training showed minimal muscle decline, with only 0.6 to 1 kilogram of lean mass lost.
• Combination Approach: The pairing of adequate protein and resistance training works synergistically. Research combining semaglutide with an investigational antimyostatin antibody showed that 92.8% of weight lost was fat compared with 71.8% with semaglutide alone, validating that muscle preservation during GLP-1 therapy is achievable when the right interventions are in place.

Protein intake is the single most modifiable variable in the muscle loss equation. Study findings consistently show that high protein intake significantly reduces lean mass loss during GLP-1 therapy. The challenge is that patients on GLP-1s often feel full quickly and may not realize they need to prioritize protein despite their suppressed appetite.

What Do the Clinical Trial Numbers Actually Show?

In the STEP-1 trial of semaglutide 2.4 milligrams weekly, participants lost approximately 15% of their body weight over 68 weeks. Bone density scans showed lean mass decreased by roughly 13%, accounting for about 40% to 45% of total weight lost. In the SURMOUNT-1 trial of tirzepatide, average weight loss was around 21%, with lean mass loss representing approximately 25% of total weight lost, a somewhat more favorable ratio.

These numbers alarmed people when they surfaced, and understandably so. Losing 8 to 15 pounds of lean mass alongside fat sounds like a serious clinical problem. However, the context changes the picture. In the STEP-1 trial, the proportion of lean mass relative to total body weight actually improved slightly, meaning patients ended up with better overall body composition even as absolute lean mass declined. Tirzepatide's dual mechanism of action appears to have some muscle-building signaling properties that explain its modestly more favorable lean mass profile compared with semaglutide.

"Protein intake is the single most modifiable variable. Study findings consistently show that high protein intake significantly reduces lean mass loss during GLP-1 therapy," explained Mohammed Chammout, a clinical access and reimbursement specialist who has worked with Optum Rx and writes about GLP-1 therapeutics for Pharmacy Times.

Mohammed Chammout, PharmD, BCMTMS, Clinical Access and Reimbursement Specialist

Are Newer Weight-Loss Drugs Better for Muscle Preservation?

The muscle loss ratio is now a design consideration for next-generation obesity medications. Pemvidutide, a GLP-1/glucagon dual agonist that received FDA breakthrough therapy designation in January 2026, has a lean mass loss ratio of approximately half that seen with semaglutide, roughly 20% compared with 39%. The glucagon component promotes fat oxidation while having a relative sparing effect on muscle protein, which explains the better body composition profile.

For patients and prescribers paying attention, the evolving landscape of obesity pharmacotherapy is moving toward agents that not only produce more weight loss but also produce better quality weight loss with more fat and less lean mass. That distinction will matter more as these drugs are prescribed to older and more vulnerable populations.

The conversation about muscle loss on GLP-1 drugs is not complicated, but it is one that should happen before patients fill their first prescription. Every patient starting therapy with a GLP-1 deserves three specific pieces of counseling: set a daily protein target, start or maintain resistance training, and understand that preserving muscle is an achievable goal with the right approach.